Inoel Rivera, MD


Focuses on cancers of the prostate, kidneys, bladder and urinary tract
Inoel Rivera, MD

Dr. Rivera is a board-certified urologist and Fellow of the American College of Surgeons who received his fellowship training in urologic oncology at the University of Florida/Shands Hospital, where he also served as an assistant professor of urology for four years. By his own words, Dr. Rivera works to ensure that his patients see him as an honest, caring and intelligent physician who is focused on innovation and medical breakthroughs. He specializes in minimally invasive, laparoscopic and robotic surgeries to address cancers of the prostate, kidneys, bladder and urinary tract with an emphasis on preserving urinary and sexual function. He also has broad experience as an investigator for clinical trials of new cancer-fighting protocols.

Dr. Rivera has been practicing urology in Central Florida since 2000. He earned his medical degree and completed residencies in surgery and urology at the University of Puerto Rico before moving to Florida for his urologic oncology fellowship in Gainesville. He is a member of the American Urologic Association, Florida Urological Society, Florida Medical Association, American Medical Society, Pan American Association and American College of Surgeons.


  • Bladder Cancer
  • Clinical Trials
  • Kidney Cancer
  • Laparoscopic Surgery
  • Prostate Cancer
  • Robotic Surgery
  • Testicular Cancer
  • Urologic Oncology

Awards & Honors

  • Pfizer Scholars in Urology Award, University of Florida/Shands Hospital
  • 1996-1998 Certified Space Shuttle Medical Support Team


  • Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Efficacy and Safety Study of XXX for the Prevention of Prostate Cancer in Men with High Grade Prostate Intraepithelial Neoplasia.
  • Sub-Investigator: A Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of Study Drug for the Prevention of Bone Fractures in Men with Prostate Cancer on Androgen Deprivation Therapy.
  • Sub-Investigator: A Double-Blind, Placebo-Controlled Parallel Group Study of the Efficacy and Safety of Study Drug 0.5mg Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer.
  • Principal Investigator: An Open-label Trial on the Effect of IV Study Drug 4mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients with Bone Metastasis.
  • Principal Investigator: A Randomized, PlaceboControlled, Serum-Level Targeted Study Investigating the Safety and Pharmacokinetics of Orally Administered Study Drug in Patients with Various Malignancies.
  • Publications
  • Bladder-Sparing Treatment of Invasive Bladder Cancer
  • Radical Prostatectomy in Patients with High Preoperative PSA
  • Male Genitalia’s Malignancy
  • Cancer of the Kidney and Ureter - Surgical Oncology: Contemporary Principles & Practice
  • The Bladder Tumor Antigen (BTA) Test Compared to Voided Urine Cytology in the Detection of Bladder Neoplasms


  • Florida Medical Association
  • Puerto Rico Urological Association
  • American Urological Association,
  • Committee for the Revision of the MCAT, 1988
  • Beta-Beta-Beta Honor Society
  • Florida Urological Society
  • Collaborator – State of Florida Prostate Cancer Task Force (1999)
  • Peer reviewer for the Journal of Urology


1812 N. Mills Ave.
Orlando, FL 32803
Phone Number: 407.897.3499

(407) 897-3499